A cutting-edge biotech startup based in Seattle, originating from the research lab of a Nobel Prize laureate, has secured $12.7 million in funding and established partnerships with industry giants Pfizer and Kite Pharma. Leveraging artificial intelligence technology, Accipiter Biosciences designs proteins that target multiple sites to combat diseases more effectively.
Accipiter Biosciences, a newly revealed entity, boasts a team of experts who honed their skills at the University of Washington’s Institute for Protein Design under the guidance of David Baker, a renowned figure in protein engineering. The company’s innovative approach utilizes AI tools developed at the institute to create novel proteins capable of binding to multiple cellular targets simultaneously, potentially enhancing their therapeutic efficacy.
“Our goal is to introduce a new treatment approach,” stated Matthew Bick, the CEO and co-founder of Accipiter Biosciences, emphasizing the potential for revolutionizing the management of complex diseases through their strategy.
Research suggests that combining multiple drugs can yield superior outcomes compared to individual therapies, but the coordination of their actions at the cellular level has posed a challenge. Accipiter Biosciences aims to address this hurdle by engineering proteins that can target multiple sites concurrently, unlocking new possibilities in disease management.
